NCT04057729 is a Phase 1 clinical trial of IMP4297 in Solid Tumor, sponsored by Impact Therapeutics, Inc..

Who is sponsoring NCT04057729?

NCT04057729 is sponsored by Impact Therapeutics, Inc..

What drugs are being tested in NCT04057729?

Interventions in NCT04057729: IMP4297.

What condition does NCT04057729 study?

NCT04057729 studies Solid Tumor.

Is NCT04057729 still recruiting?

NCT04057729 is currently completed. Last updated 30 March 2020.

Last reviewed 2020-03-30 · How we verify

NCT04057729

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IMP4297 Food Effect Trial in Healthy Volunteers

Completed Phase 1 Last updated 30 March 2020

What this trial tests

Phase 1 trial testing IMP4297 in Solid Tumor in 16 participants. Completed in 27 September 2019.

Timeline

22 July 2019

Primary endpoint
27 September 2019

27 September 2019

Quick facts

Lead sponsor	Impact Therapeutics, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	16
Start date	22 July 2019
Primary completion	27 September 2019
Estimated completion	27 September 2019
Sites	1 location across China

Drugs / interventions tested

IMP4297 — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Impact Therapeutics, Inc. — full company profile →

Who can join

Adults 18 to 55, male only, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A phase I, single-site, open-label, randomized, single-dose, two-way crossover study to evaluate the effect of food on the pharmacokinetic characteristics of IMP4297 capsules in China

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Food on the Pharmacokinetics of Senaparib (IMP4297) in Healthy Chinese Subjects.
Meng X, Lin X, Jiang R, Lu Y, et al · · 2022 · cited 1× · PMID 36239914 · DOI 10.1007/s40261-022-01198-8

Verify or expand the search:

Other trials of IMP4297

Trials testing the same drug.

NCT04351165 — BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects · Phase 1 · completed
NCT04089189 — Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer · Phase 2 · completed
NCT03508011 — A Study of IMP4297 in Patients With Advanced Solid Tumors · Phase 1 · completed
NCT03507543 — The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors · Phase 1 · completed

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Impact Therapeutics, Inc. trials

Trials by the same sponsor.

NCT07019194 — An Bioequivalence Study to Compare 10mg & 20mg of Senaparib Capsules in Healthy Chinese Subjects Under Fasting Condition · Phase 1 · completed
NCT05390944 — An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition · Phase 1 · completed
NCT05391048 — An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition · Phase 1 · completed
NCT05269316 — Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT05109832 — A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04057729 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Impact Therapeutics, Inc.
Last refreshed: 30 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04057729.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing